Prevention and Treatment of Patient Before, During, and After Covid-19 Infection

Study Overview
=================
Brief Summary
-----------------
AntiCov-220 prevents and treats before, during, and after infection with SARS-Cov-2. The composition is fractionally extracted from herbs, using flavonoids, isoflavonoids, and pregnenolone in combination with ascorbic acid as the key compounds in preventing and killing SARS-CoV-2; increase antibodies and protect cells; supplementing precursors to help the body strengthen antibodies and reduce the risk of infection; destroy spike protein, toxic protein, help prevent blood clots causing stroke; restore the physiological function of cells after virus infection; helps the body to stabilize the amount of cortisol in the blood as well as stabilize the production of specific antibodies. The composition participates in anti-inflammatory and cells protecting process, bringing blood cortisol, B-lymphocytes, Cyfra 21-1, WBC, CRP, fever, dyspnea, and other signs of respiratory tract inflammation to a normal state and normal limit.

Detailed Description
-----------------
AntiCov-220 can eliminate COVID-19 and its variants at a very early stage when they have not had enough time to multiply and cause disease. AntiCov-220 contains precursors, flavonoids, special enzymes responsible for protecting human cell membranes and destroying cell membranes of some viruses, especially, COVID-19 cannot replicate in the presence of AntiCov-220 in the body. AntiCov-220 contains precursors of cortisol. As the investigators know, cortisol has a cell anti-inflammatory, blood pressure regulation, blood sugar regulation, energy booster, and anti-stress role. It provides precursors to help direct and balance the amount of cortisol in the body that has been imbalanced before. AntiCov-220 contains flavonoids and Isoflavonoids that are cytoprotective antioxidants, clinically proven to destroy SARS-CoV-2, HBV, HIV, HCV, viruses, reduce complications after COVID-19 infection, prevent neurological sequelae, stroke, cardiovascular sequelae, respiratory sequelae, ... The anti-inflammatory, stress-reducing, cell-protective, anti-viral, and immunosuppressive process are performed by an in vivo method that has proven its effectiveness more than ten years ago. AntiCov-220 is an innovative product that can fight against COVID-19 and its variants in the current epidemic situation. AntiCov-220 is committed to protecting the community of people infected with HBV, HIV, HCV, SARS-CoV-2 against the risk of the COVID-19 pandemic and its mutations. AntiCov-220 easy to implement, highly effective, and helps reduce public health costs, which is essential in protecting human health. AntiCov-220 can be used alongside with current standard treatment regimens prescribed by the World Health Organization.

Official Title
-----------------
Prevention and Treatment of Patient Before, During, and After Covid-19 Infection

Conditions
-----------------
Covid19

Intervention / Treatment
-----------------
* Drug: AntiCov-220 (1)
* Drug: AntiCov-220 (2)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients with underlying medical conditions who have been taking medications for these conditions. Patients with AIDS, HIV, HBV, HCV, and patients with co-infections. The cancer patients are stable. Patients with congenital or acquired immunodeficiency. Exclusion Criteria: Unstable cancer patients.

Ages Eligible for Study
-----------------
Minimum Age: 16 Years
Maximum Age: 82 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: AIDS, HIV, HBV, HCV, co-infections.<br>Experimental benefits in resistance to SARS-COV-2 were observed in all patients who had previously received certain components of the AntiCov-220 (1) for various therapeutic purposes. | Drug: AntiCov-220 (1)<br>* The daily maintenance, AntiCov-220 (1) dose is to take 3 times a day, 1 tablet each time.<br>|
| Experimental: stable cancer, acquired or congenital immunodeficiency.<br>Experimental benefits in resistance to SARS-COV-2 were observed in all patients who had previously received certain components of the AntiCov-220 (2) for various therapeutic purposes. | Drug: AntiCov-220 (2)<br>* The daily maintenance, AntiCov-220 (2) dose is to take 3 times a day, 1 tablet each time.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assessment on the level of safety and tolerability of patients against the effects of Covid-19.(Arm 1) | COVID-19 is a contagious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Anticov-220 characterized by the targeting and destruction of COVID-19 One case of Covid-19 infection with no severe change in a patient with HBeAg (+). A case of HIV/AIDS turns back to HIV. Of the 35 follow-up subjects in this group, 20 were vaccinated and 15 were not. (The two cases mentioned above have not been vaccinated). | - 18 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assessment on the level of safety and tolerability of patients against the effects of Covid-19.(Arm 2) | COVID-19 is a contagious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Anticov-220 characterized by the targeting and destruction of COVID-19 _ No one has been infected with Covid-19. Of the 47 follow-up subjects in this group, 40 were vaccinated and 7 were unvaccinated. | - 18 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
HIV, Stress, AIDS, HBV, HCV, Stroke, Metabolic dissorder